Characteristics of other responders
. | Patient no. . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient characteristics . | 5 . | 10 . | 19 . | 11 . | 14 . | 21 . | 20 . | ||||||
| Age, y/sex | 12/F | 14/M | 16/F | 8/F | 17/M | 12/F | 12/F | ||||||
| Diagnosis | AML | AML | ALL | ALL | ALL | ALL | AML | ||||||
| Karyotype | t(11;20) | Diploid | Diploid | Diploid | del(6) | Haploid | Random | ||||||
| Salvage status | 1 | 2 | 2 | 2 | 4 | 5 | 2 | ||||||
| Prior BMT | No | Yes | No | No | No | Yes | Yes | ||||||
| CRD1-CRD4, wk* | 52 | 8, 9 | 146, 27 | 169, 24 | 0, 114, 0 | 45, 156, 27, 0 | 58, 47 | ||||||
| Clofarabine dose, mg/m2/d | 40 | 40 | 52 | 52 | 70 | 52 | 52 | ||||||
| Response | PR | PR | PR | HI | HI | HI | HI | ||||||
| Courses to response | 1 | 1 | 2 | 1 | 1 | 1 | 1 | ||||||
| Response duration, wk | 18 | 5 | 3 | 22 | 4 | 14 | 42+ | ||||||
. | Patient no. . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient characteristics . | 5 . | 10 . | 19 . | 11 . | 14 . | 21 . | 20 . | ||||||
| Age, y/sex | 12/F | 14/M | 16/F | 8/F | 17/M | 12/F | 12/F | ||||||
| Diagnosis | AML | AML | ALL | ALL | ALL | ALL | AML | ||||||
| Karyotype | t(11;20) | Diploid | Diploid | Diploid | del(6) | Haploid | Random | ||||||
| Salvage status | 1 | 2 | 2 | 2 | 4 | 5 | 2 | ||||||
| Prior BMT | No | Yes | No | No | No | Yes | Yes | ||||||
| CRD1-CRD4, wk* | 52 | 8, 9 | 146, 27 | 169, 24 | 0, 114, 0 | 45, 156, 27, 0 | 58, 47 | ||||||
| Clofarabine dose, mg/m2/d | 40 | 40 | 52 | 52 | 70 | 52 | 52 | ||||||
| Response | PR | PR | PR | HI | HI | HI | HI | ||||||
| Courses to response | 1 | 1 | 2 | 1 | 1 | 1 | 1 | ||||||
| Response duration, wk | 18 | 5 | 3 | 22 | 4 | 14 | 42+ | ||||||
CRD1-CRD4 indicates duration of first through fourth CRs.
Data are duration of first, second, third, and fourth remission, respectively.